patient engagement the blockbuster drug of the century
The insight of the year goes to Leonard Kish, a health IT strategy consultant, for making that statement regarding patient engagement. The corollary to this statement is a game changer: What happens when effective patient engagement becomes the Standard of Care? Used to determine whether a doctor is liable [...]
The "Wall Street Journal" suggests that entrepreneurs and innovators are not paying enough attention to the growing and pressing needs of pharmaceutical companies in the digital health arena. But is
this really the case?
Following an inspiring meeting in June 2014 on the future of the pharma industry, David Rowley, CEO of OPEN Health has published his white paper, “Health innovation: big ideas”, a call to action to the pharma industry to innovate, adapt, flex and grow. With exciting predictions for the future of healthcare worldwide, this paper marks a sea change in the way our industry must think and act if it is to meet the fast-changing needs of patients in the real world.
Pharmaceutical firms must adopt and consistently execute practices that lead to digital excellence and give them a competitive edge. Which of these firms are accelerating away from the rest of the marketplace? We found that only two—Merck and Bristol-Myers Squibb—are doing reasonably well and achieving excellence and maturity in their digital capability. Firms taking a disciplined approach to digital transformation achieved higher maturity in digital capability than their less-disciplined peers.
For the last several years, I’ve been arguing that digital health provides an important opportunity to improve drug development, for several reasons.
First, by providing greater insight into the patient’s actual experience of disease, these technologies can reveal important differentiating features of new therapeutics, or point out aspects of illness that new medicines ought to attack.
Second, by offering a richer readout of phenotype, digital health measurements can reveal important disease subgroups, perhaps defined by a unique underlying mechanism that can be targeted. I’ve discussed this in detail recently, and won’t focus on this again here.
Digital health technologies can of course be helpful in a range of other ways, such as improving adherence, population analytics, clinical decision support, etc.
While some have hailed the adoption of digital health by pharma, that’s not my impression, at least on the R&D side. In my view, it remains very much on the “innovation initiative” side of things, rather than a clear business need (like pharmacology); drug development companies may be dipping their toes in and celebrating their bravery, but at best they are interested – certainly not what I’d call “pig committed.”
"Companies pursuing digital marketing strategies for their pharmaceutical products might want to exercise some additional caution. By now, companies are well aware that the Food and Drug Administration scrutinizes the drug claims companies make on their websites. But the regulator is also paying attention to pharma posts on social media. Recently, the FDA issued warning letters to six companies for inappropriate marketing claims they made using Facebook."
Le comité économique des produits de santé (CEPS), organisme interministériel placé sous l’autorité conjointe des ministres chargés de la santé, de la sécurité sociale et de l’économie, est principalement chargé par la loi de fixer les prix des médicaments et les tarifs des dispositifs médicaux à usage individuel pris en charge par l’assurance maladie obligatoire.